← All news

FROM THE NEWS FEED

Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

2026-09-15 • Psychedelic Invest

Article summary

CAMBRIDGE, Mass., September 15, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address…

Continue to the original publication for the complete article.